The Budd-Chiari Syndrome (BCS) and the splancnic vein thrombosis are characterized by hepatic venous outflow obstruction, generally due to venous thrombosis. These rare diseases are usually caused by multiple concurrent factors, including acquired and inherited thrombophilias. Since the diagnosis of myeloproliferative neoplasms (MPNs) is often difficult in patients with BCS and splancnic vein thrombosis because of spleen enlargement, secondary pancitopenia and bleeding disorders, recent observations have included in the diagnostic work-up the analysis of the JAK2 mutation. The revision of several recent reports clarify the importance of the JAK2V617F detection in the diagnostic work-up of the BCS and splancnic vein thrombosis, allowing the demonstration of masked MPNs among these cases that may benefit, in the near future, of target molecular therapies directed toward the JAK2 mutation. Clin Ter 2010; 161(2):169-171
Budd-Chiari syndrome and splancnic vein thrombosis: masked myeloproliferative neoplasms and JAK2V617F / A., Fama; A., Rago; F., Gioiosa; C., Marzano; R., Latagliata; C., Mammi; C., Lagana; G. M., D'Elia; L., Bizzoni; S., Trasarti; A., Ferretti; M., Breccia; Riggio, Oliviero; Tafuri, Agostino. - In: LA CLINICA TERAPEUTICA. - ISSN 0009-9074. - 161:2(2010), pp. 169-171.
Budd-Chiari syndrome and splancnic vein thrombosis: masked myeloproliferative neoplasms and JAK2V617F
M. Breccia;RIGGIO, Oliviero;TAFURI, Agostino
2010
Abstract
The Budd-Chiari Syndrome (BCS) and the splancnic vein thrombosis are characterized by hepatic venous outflow obstruction, generally due to venous thrombosis. These rare diseases are usually caused by multiple concurrent factors, including acquired and inherited thrombophilias. Since the diagnosis of myeloproliferative neoplasms (MPNs) is often difficult in patients with BCS and splancnic vein thrombosis because of spleen enlargement, secondary pancitopenia and bleeding disorders, recent observations have included in the diagnostic work-up the analysis of the JAK2 mutation. The revision of several recent reports clarify the importance of the JAK2V617F detection in the diagnostic work-up of the BCS and splancnic vein thrombosis, allowing the demonstration of masked MPNs among these cases that may benefit, in the near future, of target molecular therapies directed toward the JAK2 mutation. Clin Ter 2010; 161(2):169-171I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.